Skip to main content

Selecting appropriate expression systems for large-scale production of lead antibodies

17 Jun 2024
Salon B
Lead Identification & Optimization
  • Agonistic antibodies to checkpoint inhibitors – how to select the best epitope and achieve engagement in the immune synapse?
  • Agonistic bispecific antibodies to cytokine receptors – how to achieve specificity and selectivity?
  • Which antibody formats are best suited for agonistic antibodies?
  • Can a non-neutralizing antibody to a cytokine/ soluble target be used to increase its serum half-life and activity?
Industry Expert
Trudi Veldman, Executive Director, Biologics Discovery and Head, Neglected Diseases R&D - AbbVie